Relationship between serum neopterin levels and inflammatory bowel diseases activity

Öz

Background/aims: The etiology of inflammatory bowel diseases, chronic intestinal diseases characterized by remissions and activation periods, is still unknown. Identification of the active period is important because it guides the therapy and point outs the prognosis. To date, there is still a lack of agreement on determining the active state. Neopterin is produced in monocytes/macrophages primarily upon stimulation with interferon-gamma. It is a marker associated with cell-mediated immunity. The aim of this study was to investigate the role of serum neopterin levels in Crohn's disease and ulcerative colitis disease activity. Materials and methods: Sixty-one patients with ulcerative colitis (21 female, 40 male) and 27 patients with Crohn's disease (9 female, 18 male) who were followed up at Türkiye Yüksek İhtisas Hospital were enrolled into the study. Fiftytwo healthy controls (22 female, 30 male) were also enrolled. Neopterin is measured by enzyme-linked immunosorbent assay. Serum levels >10 nmol/L are regarded as elevated. Patients with malignancy and systemic infectious diseases were not included in the study. For statistical analysis, one-way ANOVA, Pearson correlation analysis test, Fisher's exact test, Mann-Whitney U test and Student's test were used. Significance was established at p

Anahtar Kelimeler

• Neopterin, inflammatory bowel diseases, Crohn's disease, ulcerative colitis

İnflamatuvar barsak hastalıkları aktivitesi ile serum neopterin düzeyi arasındaki ilişki

Öz

Anahtar Kelimeler

• Neopterin, inflamatuvar barsak hastalığı, crohn hastalığı, ülseratif kolit

Kaynakça

1. Hugot JP, Zouali H, Lesage S, et al. Etiology of the inflammatory bowel diseases. Int J Colorectal Dis 1999; 14: 2-9.
2. Rachmilewitz D. Coated mesalazine (5-aminoalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a rando- mised trial. BMJ 1989; 298: 82-6.
3. Truelove SC, Witts LJ. Cortisone in Ulcerative Colitis: Final Report on Therapeutic Trial. BMJ 1955; 2: 1041.
4. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology 1976; 70: 439-44.
5. Hoffmann G, Wirleitner B, Fuchs D. Potential role of immune sys- tem activation-associated production of neopterin derivatives in hu- mans. Inflamm Res. 2003; 52: 313-21.
6. Niederwieser D, Fuchs D, Hausen A, et al. Neopterin as a new bi- ochemical marker in the clinical assessment of ulcerative colitis. Im- munobiology 1985; 170: 320-26.
7. Tilg H, van Montfrans C, van den Ende A, et al. Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut 2002; 50: 191-5.
8. Forrest CM, Youd P, Kennedy A, et al. Purine, kynurenine, neopte- rin and lipid peroxidation levels in inflammatory bowel disease. J Biomed Sci 2002; 9: 436-442.

9. Propst A, Propst T, Herold M, et al. Interleukin-1 receptor antago- nist in differential diagnosis of inflammatory bowel diseases. Eur J Gastroenterol Hepatol 1995; 7: 1031-6.
10. Konecny M, Ehrmann J, Bartek J, et al. The level of neopterin in blood serum as one of the possible prognostic markers of Crohn's disease activity. Acta Univ Palacki Olomuc Fac Med 1996; 140: 47- 8.
11. Judmaier G, Meyersbach P, Weiss G, et al. The role of neopterin in assessing disease activity in Crohn's disease: classification and reg- ression trees. Am J Gastroenterol 1993; 88: 706-11.
12. Reimund JM, Arondel Y, Escalin G, et al. Immune activation and nutritional status in adult Crohn's disease patients. Dig Liver Dis 2005; 37: 424-31.
13. Reimund JM, Hirth C, Koehl C, Baumann R, Duclos B.Antioxidant and immune status in active Crohn's disease. A possible relations- hip. Clin Nutr 2000; 19: 43-8.
14. Reibnegger G, Bollbach R, Fuchs D, et al. A simple index relating clinical activity in Crohn's disease with T cell activation: hematoc- rit, frequency of liquid stools and urinary neopterin as parameters. Immunobiology 1986; 173: 1-11.
15. Iris Doton, Lloyd Mayer: Immunopathogenesis of inflammatory bo- wel disease. Current opinion in Gastroenterology 2002; 18: 421-7.
16. Grisham MB. Oxidants and free radicals in inflammatory bowel di- sease. Lancet 1994; 344: 859-61.
17. Williams JG, Hughes LE, Hallet MB. Toxic oxygen metabolyte pro- duction by circulating phagocytic cells in inflammatory bowel dise- ase. Gut 1990; 31: 187-93.
18. Millner MM, Franthal W, Thalhammer GH, et al. Neopterin con- centrations in cerebrospinal fluid and serum as an aid in differenti- ating central nervous system and peripheral infections in children. Clinical Chemistry 1998; 44: 161-7.